(Total Views: 585)
Posted On: 07/07/2024 8:18:39 PM
Post# of 154003
We are only dealing with the liver alone. Not the entire body.
That means we are only looking to bind to the CCR5 receptors in the liver alone, but of course the dose will also bind to the other parts of the body as well.
When disease is bad, Stage 4, or 5, leading towards Cirrhosis, there will be many many more CCR5 on the hepatocytes and Kupfer cells, stellate cells.
When disease is light, Stage 1-3, no fibrosis, there will be minimal CCR5.
That is likely why 350 outperformed 700mg. The inflammed CCR5 took up all the leronlimab at low dose, while the uninflammed early stage disease had no CCR5 to receive the flood of leronlimab.
That means we are only looking to bind to the CCR5 receptors in the liver alone, but of course the dose will also bind to the other parts of the body as well.
When disease is bad, Stage 4, or 5, leading towards Cirrhosis, there will be many many more CCR5 on the hepatocytes and Kupfer cells, stellate cells.
When disease is light, Stage 1-3, no fibrosis, there will be minimal CCR5.
That is likely why 350 outperformed 700mg. The inflammed CCR5 took up all the leronlimab at low dose, while the uninflammed early stage disease had no CCR5 to receive the flood of leronlimab.
(6)
(0)
